7.83k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have set 52-week highs within the last week. This list is generated daily, ranked by market cap and limited to the top 30 stocks that meet the criteria.
Wells Fargo & Company
Bristol-Myers Squibb Company
Capital One Financial Corporation
State Street Corporation
TAL Education Group
Skyworks Solutions, Inc.
Citizens Financial Group, Inc.
Nomura Holdings, Inc.
Campbell Soup Company
Alnylam Pharmaceuticals, Inc.
Vipshop Holdings Limited
United Microelectronics Corporation
Sibanye Gold Limited
Western Alliance Bancorporation
Pinnacle Financial Partners, Inc.
Companhia Paranaense de Energia - COPEL
DICK'S Sporting Goods, Inc.
Pan American Silver Corp.
South African mining companies Harmony Gold, Impala Platinum, and Sibanye-Stillwater have been forced to cut production since Monday due to power shortages, they said on Tuesday. "There are very few underground mines that operated overnight and will be operating normally today," said a spokesman for the Minerals Council, an industry body. Harmony Gold called off its underground shifts, saying it would resume as soon as state power company Eskom could provide assurance power supply would be more reliable.
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. The lowest dose of the therapy, bb21217, had a median duration of response of 11.1 months and an overall response rate of 83% in heavily pre-treated patients with at least three prior lines of therapy, according to data presented at the American Society of Hematology Conference. Bb21217 belongs to a class of drugs called CAR-T therapies that involve drawing white blood cells from a patient, processing them to target cancer cells, and infusing them back into the patient.
The administration on Nov. 26 ousted Louisville-based Passport Health Plan and the Kentucky entity of Indianapolis-based Anthem Inc., which administer Medicaid benefits to nearly 500,000 Kentuckians.
Despite the sale, First Republic Bank still sees plenty of growth in its business of refinancing student loans.
IBD Stock Of The Day: Dick's Sporting Goods tested a new buy point, offering another chance to start a position as Dick's earnings growth revives.
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
With 5G wireless mobile phones on the way, the time has come to buy shares of the key radio component vendors, according to BofA Global Research.
How do we determine whether Vipshop Holdings Limited (NYSE:VIPS) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
The three major U.S. stock market indexes fell as investors fear that there won’t be enough progress made in trade talks between the U.S. and China to prevent tariffs that are scheduled for Dec. 15 from taking effect.
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
Broadcom (AVGO) fiscal fourth-quarter results are expected to reflect expanding presence in the infrastructure software space on synergies from CA buyout, amid Huawei ban and stiff competition.
The stock market opened modestly lower early Monday before mostly turning higher. Chevron was an early loser in morning trade after a downgrade.
(Bloomberg) -- Qorvo Inc. and Skyworks Solutions Inc. were both upgraded by two notches at BofA, to buy from underperform, with the firm seeing massive growth potential due to 5G technology.Because of “the exponential growth in components required to upgrade” about 1.4 billion smartphones, as well as “several hundred million” devices on the “internet of things,” BofA views 5G as “one of the more compelling and investable themes in semis.”Shares of Qorvo jumped as much as 4.4% on Monday, with the stock hitting record levels. Skyworks gained as much as 4% and hit its highest since March 2018. Both have been strong performers in 2019. Qorvo shares have jumped about 80% thus far this year while Skyworks is up more than 55%.Both stocks are major suppliers to Apple Inc. According to supply-chain data compiled by Bloomberg, Qorvo derives 32% of its revenue from Apple, while 51% of Skyworks’ revenue comes from the company. Apple is widely expected to debut a 5G version of its iPhone next year.While the first phase of 5G-related investments should favor infrastructure chipmakers like Marvell Technology, Analog Devices and Xilinx, “the next phase could also favor handset” stocks with radio frequency (RF) technology, wrote analyst Vivek Arya. There is “material upside to estimates from 5G adoption.”BofA estimated that sales of RF chips would come in at $12.6 billion in 2019, and grow to $18.5 billion over the next three years.The firm lifted its price target on Qorvo to a Street-high view of $130 from $80. The Skyworks target was boosted to $122 from $92, close to Craig-Hallum Capital Group’s $125 Street-high target.(Adds Monday trading in third paragraph, adds chart)To contact the reporter on this story: Ryan Vlastelica in New York at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Steven FrommFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Buckle (BKE) fails to retain positive comps trend in November. The decline in online sales for the month under review hurt total and comparable store net sales.
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.